Abstracts tagged "Patient reported outcomes"

Abstract Number: PP02 • ACR Convergence 2025
When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens
Kyanna Johnson, Lynn Wilson, Manuel Lubinus, Elisa Glass
Background/Purpose: My journey with dermatomyositis (DM) began abruptly in July 2024, when I was hit by sudden, severe muscle weakness after a GI infection. I…
Abstract Number: 2366 • ACR Convergence 2025
Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Skyler Peterson⁴, Robert Low³ and Alexis Ogdie⁵, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴CorEvitas, LLC, Waltham, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory condition primarily affecting the joints and skin.1 More severe symptoms are associated with lower health-related quality of…
Abstract Number: 1661 • ACR Convergence 2025
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Yujie Su², sam Barskiy³, Emily Holladay³, Shilpa Venkatachalam⁴, David Curtis⁵, Tapan Mehta³ and Fenglong Xie⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Meriden, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) programs have the potential to capture data between clinical visits and provide information back to…
Abstract Number: 1370 • ACR Convergence 2025
Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
Spencer Simko¹, Sohini Mukherjee², Ray Zhang², Puneet Bajaj³ and Bonnie Bermas⁴, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern Medical Center, Dallas, TX, ⁴UTSouthwestern.edu, Dallas, TX
Background/Purpose: Current rheumatology treatment guidelines recommend lab monitoring for methotrexate toxicity at three-month intervals for established patients. We sought to evaluate whether monitoring labs at…
Abstract Number: 1023 • ACR Convergence 2025
Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Margarita Isabel Alarcon-Jarquin¹, Fernanda M. Garcia-Garcia², Vanessa L. Lopez-Flores¹, Aranxa Galindo-Bandt³, Mario A. Arellano-Alvarez³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado² and Janett C. Riega-Torres⁴, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health impairment is common in patients with immune-mediated rheumatic diseases (IMRDs) due to chronic inflammation and immune dysregulation. These complications can worsen systemic…
Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Jordan Jones², Michael Holland³, Cara Hoffart², Maria Ibarra³ and Ashley Cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…
Abstract Number: 0360 • ACR Convergence 2025
Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
Timothy Howell¹, anne Skalicky², Louis Matza¹, John Stone³, Martha Stone⁴, Vijayaraghava Rao⁵ and Glenn Phillips⁵, ¹evidera, Washington, DC, ²evidera, Seattle, WA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Steritas, LLC, Concord, MA, ⁵argenx, Boston, MA
Background/Purpose: While glucocorticoids (GCs) are commonly used to treat a range of inflammatory diseases, the burden of toxicities associated with these medications is significant. The…
Abstract Number: PP01 • ACR Convergence 2025
When You Become the Story: A Journalist’s Approach to Managing Complex Care
Lindsay Guentzel
Background/Purpose: As a journalist, I’ve spent my career digging for answers. But when I became the story, I had to learn how to ask the…
Abstract Number: 2342 • ACR Convergence 2025
Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Andrew Ostor¹, Jessica A. Walsh², Christopher Saffore³, Xiaolan Ye⁴, Manish Patel⁵, Ana Biljan⁶, Jamie Vora⁷, Isabel Truman⁸, Molly Edwards⁸, Gary Milligan⁸ and William Tillett⁹, ¹Australian National University, Canberra, Australia, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Buffalo Grove, IL, ⁷AbbVie Inc., Palatine, IL, ⁸Adelphi Real World, Bollington, United Kingdom, ⁹Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: This study evaluated real-world effectiveness and patient- and physician-satisfaction with risankizumab (RZB) for biologic-naïve PsA patients with limited joint involvement or oligoarthritis.Methods: Data were…
Abstract Number: 1648 • ACR Convergence 2025
Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett¹, Marie-France Valois², Clifton Bingham³, Janet Pope⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Glen Hazlewood⁹, Bindee Kuriya¹⁰, Carter Thorne¹¹ and Vivian Bykerk¹², ¹McGill University, Beaconsfield, QC, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³Johns Hopkins University, Baltimore, MD, ⁴University of Western Ontario, London, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷Retired, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Toronto - Toronto, Toronto, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: Pain, fatigue, and emotional distress are common in new RA patients. It is unclear whether co-occurring symptoms predict worse outcomes and progression to advanced therapies…
Abstract Number: 1326 • ACR Convergence 2025
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², Yoshifumi Ohashi³, Shuji Asai² and Shiro Imagama², ¹Sobue Orthopedic Clinic Yatomi, Aichi, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Aichi Medical University, Graduate School of Medicine, Aichi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints but also has substantial implications for physical function. Persistent inflammation may…
Abstract Number: 0686 • ACR Convergence 2025
Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Ariane Herrick¹, Paul New², Graham Dinsdale³, Andy Vail², Joanne Manning³, Michael Hughes⁴, Will dixon⁵, Chris Taylor⁵, Mark Dickinson⁵ and Andrea Murray⁶, ¹The University of Manchester, UK, Aberdeen, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵The University of Manchester, Manchester, ⁶University of Manchester, Salford, United Kingdom
Background/Purpose: To facilitate clinical trials we previously developed a smartphone app to allow ‘tracking’ of systemic sclerosis (SSc)-related digital ulcers (DUs) and their associated pain…
Abstract Number: 0396 • ACR Convergence 2025
Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
Catherine Lavallee¹, Samuel Garfinkle², Devlin Eckardt³, Stefanie Davidson⁴, Melissa Lerman⁵, Nicole Reitz⁶ and Kerry Hurlbut⁵, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Children's Hospital of Philadelphia, Philadelphia, ⁴University of Pennsylvania/CHOP, Philadelphia, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Mental Health, St. Louis, MO
Background/Purpose: Chronic noninfectious uveitis (CU) in pediatric patients is often asymptomatic and can cause vision loss, requiring frequent ophthalmologist visits and long-term treatment. This survey…
Abstract Number: 0308 • ACR Convergence 2025
Artificial Intelligence Assisted Extraction of Patient-Reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models
Jainesh Doshi¹, Stephen Batter¹, Yiyuan Wu², Alice Santilli¹, Sandhya Kannayiram³, Susan Goodman⁴ and Bella Mehta⁵, ¹Hospital for Special Surgery, New York, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Unstructured data in physician notes can be incredibly valuable, especially for understanding patient-reported outcomes (PROs), which are often mentioned in these notes.In this study,…
Abstract Number: 0223 • ACR Convergence 2024
A Comparative Study of Difficult-to-Treat vs Non-Difficult-to-Treat Psoriatic Arthritis for Disease Burden and Comorbidities: An Ultrasound Study
Ricardo Sabido-Sauri¹, Seyyid Bilal Acikgoz², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel¹, Sylvia Sangwa⁴, Elliot Hepworth¹ and Sibel Aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increased number of patients with psoriatic arthritis (PsA) who have been failed by multiple treatment…

« Previous Page
1
…
5
6
7
8
9
…
50
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].